Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.
Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.
| Year | Screened | Likely relevant |
|---|---|---|
| 2026 | 99 | 61 |
| 2025 | 100 | 81 |
| 2024 | 98 | 72 |
| 2023 | 92 | 45 |
| 2022 | 100 | 52 |
| 2021 | 85 | 49 |
360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).
| PMID | Year | Article | Drugs | Study type | Cancer type | In the database | Curator status |
|---|---|---|---|---|---|---|---|
| 34524861 | 2021 | Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models. Science translational medicine Likely relevant Tests pharmacological serotonin depletion using fluoxetine and telotristat, and PD-1 blockade, evaluating CD8+ T cell influx and PD-L1 expression in murine models and cell lines. | fluoxetine; telotristat; anti-PD-1 | Mixed | pancreatic and colorectal cancer | fluoxetine 0/0/0; telotristat 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 34593432 | 2021 | REIC/Dkk-3 Gene Therapy Induces Immunogenic Cell Death in a Mouse Model of Malignant Mesothelioma. Anticancer research Likely relevant The study experimentally tests Ad-REIC and anti-CTLA-4 antibody in cell lines and mouse models, measuring immunogenic cell death and immunological changes. | Ad-REIC; anti-cytotoxic T-lymphocyte-associated protein 4 antibody | Mixed | malignant mesothelioma | Ad-REIC 0/0/0; anti-cytotoxic T-lymphocyte-associated protein 4 antibody 0/0/0 | Awaiting curator check |
| 34624222 | 2021 | Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell Likely relevant Examines microbiota modulation and immune checkpoint blockade in mice and human patients, measuring immune cell subsets and interferon production. | immune checkpoint blockade (ICB) | Mixed | melanoma | immune checkpoint blockade (ICB) 0/0/0 | Awaiting curator check |
| 34628702 | 2021 | Programmed death (PD)-1/PD-ligand 1 blockade mediates antiangiogenic effects by tumor-derived CXCL10/11 as a potential predictive biomarker. Cancer science Likely relevant Tests anti-PD-L1/PD-1 antibodies in syngeneic mouse models and human samples, measuring upregulation of CXCL10/11 chemokines. | anti-PD-L1 Ab; anti-PD-1 Ab | Animal | lung carcinoma | anti-PD-L1 Ab 0/0/0; anti-PD-1 Ab 0/0/0 | Awaiting curator check |
| 34653365 | 2021 | Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer cell Likely relevant The study experimentally evaluates paclitaxel and atezolizumab treatment in patients and measures changes in immune cell subsets and dynamics using single-cell RNA and ATAC sequencing. | paclitaxel; atezolizumab | Patient | triple-negative breast cancer | paclitaxel 21/5/8; atezolizumab 0/0/4 | Awaiting curator check |
| 34686340 | 2021 | Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. Cell reports Likely relevant Tests anti-TREM2 monoclonal antibody therapy in mouse syngeneic and orthotopic ovarian tumor models and measures anti-tumor immunity and macrophage/T-cell modulation. | anti-TREM2 monoclonal antibody; checkpoint inhibitor | Animal | solid tumors, ovarian cancer | anti-TREM2 monoclonal antibody 0/0/0; checkpoint inhibitor 0/0/0 | Awaiting curator check |
| 34732412 | 2021 | SLAMF7 and TREM1 Mediate Immunogenic Cell Death in Colorectal Cancer Cells: Focus on Microsatellite Stability. Anticancer research Likely relevant The study uses colorectal cancer cell lines to examine immunogenic traits and apoptosis when treated with anti-PD-1 drugs and TREM1 inhibitors. | anti-PD-1; TREM1 inhibitors | Cell line | colorectal cancer | anti-PD-1 14/36/0; TREM1 inhibitors 0/0/0 | Awaiting curator check |
| 34755131 | 2021 | Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. Cell reports. Medicine Likely relevant Patient cohort treated with neoadjuvant nivolumab, evaluating T cell receptor repertoire, clonal expansion, and immune cell signatures. | nivolumab | Patient | oral cavity squamous cell carcinoma | nivolumab 1/2/4 | Awaiting curator check |
| 34965422 | 2021 | USP19 exacerbates lipogenesis and colorectal carcinogenesis by stabilizing ME1. Cell reports Likely relevant The study tests an ERK2 inhibitor and anti-PD-L1 antibody in mouse models and measures PD-L1 expression and immune-related factors. | ERK2 inhibitor; anti-PD-L1 antibody | Animal | colorectal cancer | ERK2 inhibitor 0/0/0; anti-PD-L1 antibody 0/1/0 | Awaiting curator check |
| 34975854 | 2021 | PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer. Frontiers in immunology Likely relevant The study experimentally tests the PARP inhibitor pamiparib in vitro and in vivo and measures its effect on PD-L1 expression and CD8+ T cells in pancreatic cancer. | pamiparib; PD-L1 blockers; anti-PD-L1/PD-1 drugs | Mixed | pancreatic cancer | pamiparib 0/0/0; PD-L1 blockers 0/0/0; anti-PD-L1/PD-1 drugs 0/0/0 | Awaiting curator check |